SARS-CoV-2: structure, biology, and structure-based therapeutics development
MY Wang, R Zhao, LJ Gao, XF Gao… - Frontiers in cellular …, 2020 - frontiersin.org
The pandemic of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has been posing great threats to the world in many aspects. Effective therapeutic and …
has been posing great threats to the world in many aspects. Effective therapeutic and …
[HTML][HTML] Immunology of COVID-19: current state of the science
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide, igniting …
syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide, igniting …
[HTML][HTML] Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Background Agents blocking programmed cell death protein 1/programmed death-ligand 1
(PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC). However, the …
(PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC). However, the …
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
M Yi, J Zhang, A Li, M Niu, Y Yan, Y Jiao, S Luo… - Journal of hematology & …, 2021 - Springer
Background Therapeutic antibodies targeting programmed cell death protein 1 (PD-
1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor …
1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor …
Extracellular vesicles mediate antibody-resistant transmission of SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic. Antibody resistance dampens neutralizing antibody therapy and threatens …
pandemic. Antibody resistance dampens neutralizing antibody therapy and threatens …
[HTML][HTML] Neutralizing antibodies targeting SARS-CoV-2 spike protein
S **aojie, L Yu, Y Guang, Q Min - Stem cell research, 2021 - Elsevier
SARS-CoV-2 causing the worldwide pandemic has changed people's life in multiple aspects
dramatically since it's first identified in Wuhan, China at the end of 2019. While the numbers …
dramatically since it's first identified in Wuhan, China at the end of 2019. While the numbers …
Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
Development of a hyperimmune equine serum therapy for COVID-19 in Argentina
V Zylberman, S Sanguineti, AV Pontoriero… - Medicina (Buenos …, 2020 - SciELO Argentina
The disease named COVID-19, caused by the SARS-CoV-2 coronavirus, is currently
generating a global pandemic. Vaccine development is no doubt the best long-term …
generating a global pandemic. Vaccine development is no doubt the best long-term …
RBD-specific polyclonal F (ab) 2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind …
G Lopardo, WH Belloso, E Nannini, M Colonna… - …, 2021 - thelancet.com
Background passive immunotherapy is a therapeutic alternative for patients with COVID-19.
Equine polyclonal antibodies (EpAbs) could represent a source of scalable neutralizing …
Equine polyclonal antibodies (EpAbs) could represent a source of scalable neutralizing …
Deciphering SARS-CoV-2 virologic and immunologic features
G Lebeau, D Vagner, E Frumence, F Ah-Pine… - International journal of …, 2020 - mdpi.com
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 and its associated
pathology, COVID-19, have been of particular concerns these last months due to the …
pathology, COVID-19, have been of particular concerns these last months due to the …